Capstone Investment Advisors
PRME icon

Capstone Investment Advisors’s Prime Medicine PRME Stock Holding History

Capstone Investment Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,551
Closed -$179K – 1900
2023
Q1 		$179K Buy
+14,551
New +$237K ﹤0.01% 1287

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Capstone Investment Advisors's PRME Position: Q2 2023 in Review

Capstone Investment Advisors sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 14,551 shares — an estimated $179K sold.

Capstone Investment Advisors first reported a position in PRME in Q1 2023 and held it in 1 quarter. The position peaked at $179K in Q1 2023. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • Capstone Investment Advisors reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 14,551 Prime Medicine shares in Q2 2023, an estimated $179K.
  • Capstone Investment Advisors first reported a position in Prime Medicine in Q1 2023 and held it in 1 quarter.
  • Capstone Investment Advisors's Prime Medicine position peaked at $179K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on Capstone Investment Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.